PRM-001
Chronic kidney disease associated with m.A3243G mtDNA mutation
PreclinicalActive
Key Facts
Indication
Chronic kidney disease associated with m.A3243G mtDNA mutation
Phase
Preclinical
Status
Active
Company
About Primera Therapeutics
Pioneering TALE‑based mtDNA editing to cure mitochondrial diseases, starting with kidney disease.
View full company profile